Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-52.73%
0%
-52.73%
6 Months
-33.33%
0%
-33.33%
1 Year
-82.67%
0%
-82.67%
2 Years
-99.0%
0%
-99.0%
3 Years
-98.71%
0%
-98.71%
4 Years
-99.35%
0%
-99.35%
5 Years
-99.6%
0%
-99.6%
Oxford BioDynamics Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.65%
EBIT Growth (5y)
-193.07%
EBIT to Interest (avg)
-9.69
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.58
Sales to Capital Employed (avg)
0.08
Tax Ratio
2.93%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.75
EV to EBIT
-0.58
EV to EBITDA
-0.66
EV to Capital Employed
2.77
EV to Sales
6.97
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-475.74%
ROE (Latest)
-199.98%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
Bullish
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Sep'23
Sep'23
Sep'22
Change(%)
Net Sales
0.50
0.20
150.00%
Operating Profit (PBDIT) excl Other Income
-9.60
-7.90
-21.52%
Interest
0.20
0.20
Exceptional Items
-1.20
1.10
-209.09%
Consolidate Net Profit
-10.80
-6.70
-61.19%
Operating Profit Margin (Excl OI)
-21,558.80%
-58,928.60%
3,736.98%
USD in Million.
Net Sales
YoY Growth in year ended Sep 2023 is 150.00% vs -33.33% in Sep 2022
Consolidated Net Profit
YoY Growth in year ended Sep 2023 is -61.19% vs 0.00% in Sep 2022
About Oxford BioDynamics Plc 
Oxford BioDynamics Plc
Pharmaceuticals & Biotechnology
Oxford BioDynamics Plc is a biotechnology company, which is engaged in biomarker research and development. The Company focuses on the discovery and development of biomarkers for use within the pharmaceutical and biotechnology industry. Its geographical segments include UK and Malaysia. Its EpiSwitch is an industrial platform for the discovery, evaluation, validation and monitoring of a class of epigenetic biomarkers known as chromosome conformation signatures (CCSs). EpiSwitch is a biomarker technology platform that facilitates pharmaceutical and biotechnology companies in their therapeutic development programs and the development of companion diagnostics. The EpiSwitch technology has validated biomarkers in a range of diseases, including Alzheimer's disease, breast cancer, ulcerative colitis and liver cancer. Its service offering includes predictive biomarkers, prognostic biomarkers, residual disease monitoring biomarkers, diagnostic biomarkers and companion diagnostic biomarkers.
Company Coordinates 
Company Details
26 Beaumont Street , OXFORD None : OX1 2NP
Registrar Details






